You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The bill, which Congress overwhelmingly approved last week, also includes additional funding for the US Centers for Disease Control and Prevention.
The bill, which was overwhelming passed by both the Senate and the House, would boost the National Institutes of Health's budget by $1.25 billion.
Science reports on how scientists running for office in the US have fared in the election, though some results are still being counted
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
CNBC reports NIH Director Francis Collins told a congressional committee that assessing the safety and efficacy of COVID-19 vaccine is the agency's "top priority."
The move raises questions about what precisely is an LDT outside of FDA jurisdiction and heightens concerns that poorly validated tests will enter the market and endanger public health.
According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.
The editorial board of the Pittsburgh Post-Gazette says other lawmakers should take Florida's approach and provide additional protections against genetic discrimination.
The appropriations committee recommended that the NIH receive a total of $46.96 billion in NIH funding for FY 2021, a nearly 13 percent increase over its current budget.
Science reports that a draft spending bill would increase the US National Institutes of Health budget by 13 percent.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.